# A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis

> **NCT06832618** · PHASE3 · RECRUITING · sponsor: **Incyte Corporation** · enrollment: 240 (estimated)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Ruxolitinib
- **DRUG:** Vehicle Cream

## Key facts

- **NCT ID:** NCT06832618
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-17
- **Primary completion:** 2026-07-13
- **Final completion:** 2028-05-18
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2025-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06832618

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06832618, "A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT06832618. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*